Tigecycline activity against geographically diverse Acinetobacter spp. displaying multidrug-resistant phenotypes across Europe
Abstract number: P1163
Thornsberry C., Draghi D., Pillar C., Dowzicky M., Sahm D.
Objective:Acinetobacter (AC) is generally a nosocomial pathogen. There are several risk factors among patients that can be associated with increased infection of this organism such as extremely ill patients on a ventilator, those with a prolonged hospital stay, or those with open wounds. In 2006, tigecycline (TIG) was approved in Europe (EU) for treatment of complicated skin and skin structure infections and complicated intra-abdominal infections.
Methods: In total, 104 AC isolates were obtained from 28 hospitals in eleven countries across EU during 2006 to 2007. Isolates were tested centrally by broth microdilution (CLSI M7-A7). TIG activity was analysed according to susceptible (S), non-susceptible (NS), and multidrug phenotypes [MDR; resistance to 3 agents including cefepime (FEP), ciprofloxacin (CIP), gentamicin (GEN), imipenem (IMI), minocycline (MIN), and piperacillin-tazobactam (PTZ)]. Enterobacteriaceae EUCAST breakpoints (BPs) were applied to all TIG results (BPs do not currently exist for AC). CLSI (M100-S17) BPs were used to interpret all comparators (where applicable).
Results: The most common MDR phenotype was 3-drug R with concurrent R to CIP, GEN, and PTZ (12.5% of all isolates surveyed) followed by 5-drug R with concurrent R to FEP, CIP, GEN, IMI, and PTZ (9.6% of all isolates surveyed).
Conclusions: TIG maintained potent in vitro activity against AC. The TIG MIC90 ranged from 1 to 2 mg/L, regardless of resistance or MDR phenotype. Due to the resistance associated with AC, it is imperative to monitor the susceptibility patterns of this organism against new agents such as TIG.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|